Potassium Chloride

Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: KCL Retard, Micro-Kalium Retard, Rekawan Retard; Belgium: Chloropotassuril; Cyprus: KCL Retard, Slow-K; Czech Republic: KCL Retard; Denmark: Kaleorid; Finland: Durekal, Kalinorm; France: Diffu-K, Kaleorid; Germany: Kalinor, Rekawan; Greece: Acronitol; Ireland: Kay-Cee-L, Nu-K; Italy: KCL Retard, Lento-Kalium; Netherlands: Kalium-Durettes, Micro-K Extentcaps, Slow-K; Poland: Kaldyum, Kalium Chloratum; Spain: Cloruro Potásico, Potasión, Solución Cloruro Potásico; Sweden: Kaleorid; UK: Kay-Cee-L, Slow-K.

North America

Canada: K, K-10, K-Dur, K-Lor, K-Lyte/Cl, Micro-K, Roychlor, Slo-Pot, Slow-K; USA: Kaon CL-10, Kay Ciel, K-Lor, Klor-Con, MicroK.

Latin America

Argentina: Cloruro de Potasio, Control K, Co-Salt, Orakit-Orakit Molar, Potasio Cloruro Bioquim; Brazil: Cloreto de Potássio, Clotássio, Suple K; Mexico: Clor-K-Zaf, Cloruro de Potasio, Kaliolite, K-Dur, Kelefusín.


Japan: Conclyte-K1, F-Zuren K, K. C. L., KCL, K-Supply, Mediject K, Slow-K.

Drug combinations

Potassium Chloride and Potassium Bicarbonate

Other Potassium Chloride combinations: Arginine, Calcium Citrate; Calcium Chloride; Calcium Lactate; Folic Acid (Vitamin B~9~); Sodium Acetate; Sodium Bicarbonate; Sodium Chloride; Sodium Lactate; Sodium Phosphate


Potassium Chloride: KCl. Mw: 74.55. CAS-7447-40-7.

Pharmacologic Category

Replacement Preparations; Potassium Supplements. Oral Electrolyte Supplement. Parenteral Electrolyte Supplement. (ATC-Code: A12BA01).

Mechanism of action

Essential for conduction of nerve impulses in heart, brain, and skeletal muscle. Contraction of cardiac, skeletal and smooth muscles. Maintenance of normal renal function, acid-base balance, carbohydrate metabolism, and gastric secretion.

Therapeutic use

Treatment or prevention of hypokalemia.

Pregnancy and lactiation implications

Reproduction studies not conducted. Potassium supplementation (does not cause maternal hyperkalemia) not expected to cause adverse fetal events or affect normal levels of postassium in breast milk.

Unlabeled use


Hypersensitivity to any component of the formulation. Hyperkalemia. Solid oral dosage forms contraindicated in patients with delay or arrest in passage through GI tract.

Warnings and precautions

Severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (e.g. heart block, ventricular arrhythmias, asystole). Changes in serum potassium concentrations can occur during acid/base correction (use with caution in acid/base alterations). Patients may be more susceptible to life-threatening cardiac effects associated with hyper-/hypokalemia (use with caution in cardiovascular disease (e.g. heart failure, cardiac arrhythmias)). Use with caution in disorders or conditions likely to contribute to altered serum potassium and hyperkalemia (e.g. untreated Addison’s disease, heat cramps, severe tissue breakdown from trauma or burns). Use with caution in renal impairment (contraindicated with severe impairment), in digitalized patients (may be more susceptible to potentially life-threatening cardiac effects with rapid changes in serum potassium concentrations), and in patients receiving concomitant medications or therapies which increase potassium (e.g. ACEI, potassium-sparing diuretics, potassium-containing salt substitutes). Oral liquid preparations (not solid) should be used in esophageal compression or delayed gastric emptying. Use extreme caution with parenteral administration (pain and phlebitis may occur; inappropriate parenteral administration may be fatal). Should be administered further diluted (avoid administering potassium diluted in dextrose solutions during initial therapy). Potential for transient decreases in serum potassium due to intracellular shift of potassium from dextrose-stimulated insulin release.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart